Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
10 2020
Historique:
received: 25 05 2020
accepted: 05 07 2020
pubmed: 17 8 2020
medline: 15 4 2021
entrez: 17 8 2020
Statut: ppublish

Résumé

To investigate differences in local tumour staging between clinical examination and MRI and differences between FIGO 2009, FIGO 2018 and TNM in patients with primary cervical cancer undergoing definitive radio-chemotherapy. Patients from the prospective observational multi-centre study "EMBRACE" were considered for analysis. All patients had gynaecological examination and pelvic MRI before treatment. Nodal status was assessed by MRI, CT, PET-CT or lymphadenectomy. For this analysis, patients were restaged according to the FIGO 2009, FIGO 2018 and TNM staging system. The local tumour stage was evaluated for MRI and clinical examination separately. Descriptive statistics were used to compare local tumour stages and different staging systems. Data was available from 1338 patients. For local tumour staging, differences between MRI and clinical examination were found in 364 patients (27.2%). Affected lymph nodes were detected in 52%. The two most frequent stages with FIGO 2009 are IIB (54%) and IIIB (16%), with FIGO 2018 IIIC1 (43%) and IIB (27%) and with TNM T2b N0 M0 (27%) and T2b N1 M0 (23%) in this cohort. MRI and clinical examination resulted in a different local tumour staging in approximately one quarter of patients. Comprehensive knowledge of the differential value of clinical examination and MRI is necessary to define one final local stage, especially when a decision about treatment options is to be taken. The use of FIGO 2009, FIGO 2018 and TNM staging system leads to differences in stage distributions complicating comparability of treatment results. TNM provides the most differentiated stage allocation.

Identifiants

pubmed: 32798000
pii: S0090-8258(20)32382-9
doi: 10.1016/j.ygyno.2020.07.007
pii:
doi:

Substances chimiques

Cisplatin Q20Q21Q62J

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

136-141

Subventions

Organisme : Austrian Science Fund FWF
ID : KLI 695
Pays : Austria

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None. The following are the supplementary data related to this article. Supplementary data to this article can be found online at https://doi.org/10.1016/j.ygyno.2020.07.007.

Auteurs

J Knoth (J)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria.

R Pötter (R)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria.

I M Jürgenliemk-Schulz (IM)

University Medical Centre Utrecht, The Netherlands.

C Haie-Meder (C)

Department of Radiotherapy, Gustave-Roussy, France.

L Fokdal (L)

Department of Oncology, Aarhus University Hospital, Denmark.

A Sturdza (A)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria.

P Hoskin (P)

Mount Vernon Cancer Centre, Northwood, United Kingdom.

U Mahantshetty (U)

Department of Radiation Oncology, Tata Memorial Hospital, India.

B Segedin (B)

Department of Oncology, Institute of Oncology Ljubljana, Slovenia.

K Bruheim (K)

Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Norway.

E Wiebe (E)

Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, Canada.

B Rai (B)

Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

R Cooper (R)

Leeds Cancer Centre, St James's University Hospital, United Kingdom.

E van der Steen-Banasik (E)

Radiation Oncology Department, Radiotherapy Group, Arnhem, The Netherlands.

E van Limbergen (E)

Department of Radiation Oncology, University Hospitals Leuven, Belgium.

B R Pieters (BR)

Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands.

M Sundset (M)

Clinic of Oncology and Women's Clinic, St. Olavs Hospital, Trondheim, Norway.

L T Tan (LT)

Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

R A Nout (RA)

Department of Radiation Oncology, Erasmus MC, Erasmus University Rotterdam, The Netherlands.

K Tanderup (K)

Department of Oncology, Aarhus University Hospital, Denmark.

C Kirisits (C)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria.

N Nesvacil (N)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria.

J C Lindegaard (JC)

Department of Oncology, Aarhus University Hospital, Denmark.

M P Schmid (MP)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria. Electronic address: maximilian.a.schmid@meduniwien.ac.at.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH